Herein, we investigate the clinical meaning of MMR deficiency in breast cancer by immunohistochemical assessment of MSH2, MSH6, MLH1 and PMS2 on a large series of breast cancers linked to detailed biomarker and long-term outcome data. This evidence concerns the gene PMS2 and hyperinsulinemic hypoglycemia, familial, 4.